Additional Indication: Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki) Description Vial size Billing Units NDC J-code.
Enhertu is an Oncology drug manufactured by Daiichi Sankyo and administered via the Intravenous route of administration. The J Code: J9358 is aligned to the
CODE. CLEVER CHEK AUTO-CODE SYSTEM. CLEVER CHEK AUTO-CODE TEST. CLEVER CHEK J J ADHESIVE LARGE. J J ALL-PURPOSE FIRST AID. J J ANTISEPTIC WIPES. J
Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC41. Page 11. 11. Mechanism of action. Enhertu, trastuzumab deruxtecan
J . CPT CODE: J. $7.62. J Q. CPT CODE: J. $5.03. J . CPT CODE: J. $5.03 CODE: $2,300.78. S . CPT CODE: $697.04. S .
ICD-10 codes. Codes prefixed with C50. Regimen details. Day. Drug. Dose. Route. 1. Enhertu. 5.4mg/kg. IV infusion. To reduce the risk of medication errors it
ATC code. L01XC41. Mechanism of action. Enhertu, trastuzumab deruxtecan, is a HER2-targeted antibody-drug conjugate (ADC). The antibody is a
J3247: Permanent J-code for the intravenous (IV) formulation of COSENTYX (secukinumab) . Effective J, for all sites of care If COSENTYX is administered on or after J, the permanent J-code replaces the miscellaneous J-code, J3590.
Find patient medical information for Enhertu ( Reviews (8). Uses. What is Enhertu used for? Enhertu (fam-trastuzumab
R.